Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma. Issue 2 (March 2015)

• Record Type: Journal Article
• Authors: Choi, Hayoung; Chang, Jinsun; Shin, Hong‐Joon; Park, Cheol‐Kyu; Oh, In‐Jae; Kim, Kyu‐Sik; Kim, Young‐Chul
• Is Part Of: Thoracic cancer. Volume 6:Issue 2(2015)
• Page Start: 224
• Page End: 226
• Publication Date: 2015-03
• Subjects: Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.12171
• Languages: English
• ISSNs: 1759-7706

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <p>We report a case showing the long‐term clinical benefit of the continued use of gefitinib in a patient with asymptomatic progression of lung adenocarcinoma harboring an exon 19 deletion of the epidermal growth factor receptor gene. Although follow‐up studies showed smoldering progression of metastatic lesions, continued treatment with gefitinib controlled pulmonary adenocarcinoma for more than six years.</p> </abstract>